GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
43.06
-1.28 (-2.89%)
At close: Mar 13, 2026, 4:00 PM EDT
42.70
-0.36 (-0.84%)
After-hours: Mar 13, 2026, 7:59 PM EDT
GRAIL Revenue
In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth. GRAIL had revenue of $43.60M in the quarter ending December 31, 2025, with 13.97% growth.
Revenue (ttm)
$147.17M
Revenue Growth
+17.18%
P/S Ratio
12.00
Revenue / Employee
$147,172
Employees
1,000
Market Cap
1.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 147.17M | 21.58M | 17.18% |
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.04B |
| Sotera Health Company | 1.16B |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
| CareDx | 379.81M |
GRAL News
- 1 day ago - Grail CEO Bob Ragusa to retire, Josh Ofman named successor - Reuters
- 1 day ago - GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor - PRNewsWire
- 8 days ago - Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewsWire
- 11 days ago - GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 17 days ago - GRAIL to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 18 days ago - GRAIL Stock Tumbles — National Health Service Galleri Trial To Blame - Benzinga
- 18 days ago - 'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection - Fox Business
- 21 days ago - This once-hot cancer-detection company's stock got cut in half after a failed trial - Market Watch